On track to submit GraftAssureDx™ for FDA review by year-end On track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025 GraftAssure assay’s head-to-head data continue to be favorable Preparing to rapidly expand beyond kidney into heart transplant testing NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. , or iMDx, (Nasdaq: IMDX),... Read More

NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will... Read More

Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future products Brings 25 years of experience driving new product adoption across geographies in transplantation, oncology and immunology NASHVILLE, Tenn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. , (Nasdaq: IMDX), (iMDx), today announced that it has welcomed Steven Tahmooressi to its executive leadership team... Read More

American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancers GraftAssure used to help avoid overtreatment and preserve patient’s immune system As transplant care evolves to include novel therapies, the need for ongoing molecular diagnostic monitoring should continue to grow NASHVILLE, Tenn., Oct. 06, 2025... Read More

IMDX to host symposium on Wednesday, September 24 th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting Presenting on GraftAssureIQ at symposium on Thursday, October 9 th at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics... Read More

5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partners New hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for transplanted organ rejection (dd-cfDNA) Novel registry expected to collect approximately 50,000 samples over three years for organ rejection assay combining both percent and total donor derived cell-free DNA into one... Read More

iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previously GraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics , or iMDx, (Nasdaq: IMDX), today announced that it is actively enrolling patients in its clinical trial to assess GraftAssureDx and that last week, it... Read More

NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. , or iMDx, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Information for each can be found below: Event: H.C. Wainwright 27 th Annual Global Investment Conference Date: September 8 – 9, 2025 Location: In-person at the Lotte New York Palace Hotel and... Read More

BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Empowered Patient Podcast with Karen Jagoda recently featured Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) (Nasdaq: IMDX), in an episode on “ Democratizing Molecular Diagnostics: Transforming Transplant Success .” In the episode, James discussed iMDx’s mission, the company’s focus on transplant diagnostics, and its strategy to bring testing... Read More

Reiterating timelines for FDA submission in 2025 Transplant clinical trial has attracted leading transplant hospitals Booked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. , or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction... Read More

NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics , or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be... Read More

iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined score Data show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens clinical utility for dd-cfDNA with fewer false positives, further reducing unnecessary invasive biopsies for patients iMDx expects to evaluate combined score in ongoing FDA study (NCT07060716) iMDx will be... Read More

NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics , or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00 PM ET featuring Anthony Langone, MD (Associate Professor of Medicine, Division of Nephrology and Hypertension, Vanderbilt University). To register, click here. Dr. Langone, who serves as the national principal... Read More

Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients Data was presented at the European Renal Association (ERA) 2025 Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2 Upcoming... Read More

New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq:... Read More

New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunity Brings pricing in line with existing competitive technology Expands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. , (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its... Read More

Q1 2025 pharma services revenue of $2.1 million, at 62% gross margin Three of the top 10 U.S. transplant centers expected to participate in clinical trial Ten globally leading transplant hospitals are now using our GraftAssure research-use-only kits To reflect our larger market opportunity, we plan to rename the company in Q2 IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics... Read More

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. , (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will... Read More

Central Institutional Review Board approved, final preparatory steps underway at first transplant centers Three of the top 10 U.S. transplant centers expected to participate in trial Nearly 10% of annual U.S. transplant volume represented in trial site interest Preparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. , (Nasdaq: OCX), a leading... Read More

Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in Berlin Supports market expansion for testing of high-risk patient population New findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. , (Nasdaq: OCX), a leading diagnostics technology company, today announced the publication of new and... Read More

IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh... Read More

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a... Read More

IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A,... Read More

IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference... Read More

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering... Read More

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s... Read More

Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than... Read More

IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. , (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43ʳᵈ Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025. During this period, Oncocyte will host one-on-one meetings with... Read More

IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number... Read More

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated... Read More

Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase FDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today published... Read More

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp . (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial... Read More

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp . (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29 th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory... Read More

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp . (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of... Read More

GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volume Company clears first stage gate in clinical product development process and has submitted a Q-Sub to the FDA IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two... Read More

IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc., one of the Company’s strategic partners. The gross proceeds to the Company from the private placement are... Read More

IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test. Patients were tested before, during and after treatment with daratumumab, an anti-CD38 monoclonal antibody... Read More

Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following... Read More

IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August: 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors. Sidoti Micro-Cap Virtual... Read More

IRVINE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on Thursday, August 8, 2024, at 5:00 p.m. Eastern Time to discuss its financial results and highlights. Interested... Read More

HOLLAND, Mich., July 11, 2024 (GLOBE NEWSWIRE) -- MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, "Take Advantage of the Moment." In this episode, Riggs highlights Oncocyte's innovative strategies in molecular diagnostic technology and the significant impact of this technology on patient care. Hosted by Tom... Read More

IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. “We are thrilled to welcome Andrea as we approach the inflection point of commercial launch,” Oncocyte CEO Josh Riggs said. “She has a proven track record of guiding financial strategy... Read More

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte’s (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure. The... Read More

Late-breaking presentation of data at American Transplant Congress on Monday, June 3 Data show potential to monitor for therapeutic efficacy and recurrence Potential repeat testing opportunities with claims expansion IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was... Read More

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc. On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q... Read More

IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested... Read More

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Oncocyte Corporation’s Chief Executive Officer, Josh Riggs, as the company works to disrupt the mature diagnostics marketplace with a nimble, capital-light approach to growth. Oncocyte (Nasdaq: OCX) has developed and is preparing to commercialize precision tests in the transplant and oncology markets. The... Read More

IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP $15.8 million in gross proceeds received from private placement offering $4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn,... Read More

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to... Read More

Bio-Rad expects to make equity investment in support of deal Agreement provides for global exclusivity in transplant monitoring commercialization Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in... Read More

IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its... Read More

IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more information about the Sequire Investor Summit, including... Read More

Significant unmet need for regulated product in $2B US testing market Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests... Read More

Launching First Products in 1H 2024 Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test,... Read More

IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issued the same day,... Read More

Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte's VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA / ACCESSWIRE / September 18, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the... Read More

CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA / ACCESSWIRE / September 6, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel. Josh Riggs, CEO of Oncocyte, will be meeting 1x1... Read More

First digital-droplet PCR assay to receive coverage Expect initial revenue generation in Q1 2024 IRVINE, CA / ACCESSWIRE / August 28, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company's VitaGraft Kidney™ diagnostic... Read More

IRVINE, CA / ACCESSWIRE / August 9, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The Company was previously notified by Nasdaq... Read More

Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment Improved utility over standard of care tests Paper published in peer-reviewed journal IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced the publication of new data demonstrating VitaGraft Kidney’s novel ability to help physicians treat kidney... Read More

IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock. The reverse stock split will be effective at 5:00 p.m. Pacific time on July 24, 2023, and the Company’s common stock will begin to trade on a post-split basis at the... Read More

Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has begun the manufacturing process for the distributable version of its patented transplant technology. A method of checking for signs of graft damage in transplant recipients, the assay measures... Read More

IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31, 2023. First Quarter 2023 and Recent Highlights: Completed an equity capital raise of $13.86 million from the sale and issuance of common stock to strengthen the balance sheet and further support the Company’s product portfolio.... Read More

IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, before U.S. market open. The company will host a conference call following the release at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time to discuss its financial results and recent highlights.... Read More

IRVINE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at the Annual Meeting of the American Association for Cancer Research. Four abstracts explore the tumor microenvironment and its potential implications for therapeutic response, leveraging expertise and technology behind DetermaIO. A... Read More

IRVINE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its workforce, which management believes will extend Oncocyte’s cash runway in 2024. “As part of our efforts to bring our cost structure in line with our kitted product strategy and to optimize our operational efficiency, we reduced our... Read More

IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO™ to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in Clinical Cancer Research and showed the utility of DetermaIO in... Read More

IRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, announced today the entry into an agreement with certain members of the Company’s board of directors, and several institutional and accredited investors, including Broadwood Capital, L.P., the Company’s largest shareholder, relating to their purchase of an aggregate of up to... Read More

IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and Exchange Commission regarding its Annual Report on Form 10-K and reports preliminary financial results for the full year ended December 31, 2022. The Company is completing its final review of the information required to be presented... Read More

IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earnings conference call. It will now report its fourth quarter and full year 2022 financial results on Monday, April 3, 2023. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 5:30 a.m.... Read More

IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its fourth quarter and full year 2022 financial results on Wednesday, March 29, 2023. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent... Read More

IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023. Since being named interim CEO in December, Riggs has successfully led the process of restructuring the Company by refocusing product strategy and reducing costs across the organization. Riggs... Read More

Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product strategy IRVINE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has completed the sale of 70% of its ownership stake in wholly-owned subsidiary Razor Genomics to Dragon Scientific. The deal... Read More

IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte’s workforce to realign its team towards key products that address larger markets. Additionally, Oncocyte has entered into a Stock Purchase Agreement pursuant to which Oncocyte will transfer 70% of its ownership of Razor Genomics, Inc. to... Read More